{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:21:39Z","timestamp":1778808099157,"version":"3.51.4"},"reference-count":44,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To investigate the effect of 1-year treatment with the anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) drug etanercept on lipid profile and oxidative stress in children and adolescents with juvenile idiopathic arthritis (JIA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Thirty children with JIA (22 females; mean age 12.3 \u00b1 SD 5.7 yrs), all eligible for anti-TNF-\u03b1 treatment, were assessed at baseline and after 6- and 12-month treatment with etanercept. Disease activity was determined using the Juvenile Arthritis Disease Activity Score (JADAS). Blood samples were drawn to measure the acute-phase reactants C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), lipids, and the proinflammatory cytokines TNF-\u03b1, interleukin-1\u03b2 (IL-1\u03b2), IL-6 and interferon-\u03b3. To measure the oxidative stress marker 8-iso-prostaglandin F<jats:sub>2\u03b1<\/jats:sub>, 24-h urine samples were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Inflammatory indicators (CRP and ESR) and JADAS scores improved significantly after 1 year of etanercept treatment (all p &lt; 0.001). Proinflammatory cytokines showed significant reduction during the study period (all p &lt; 0.001). Similar reductions were detected in total cholesterol (p &lt; 0.001), low-density lipoprotein cholesterol (p = 0.04), and triglycerides (p &lt; 0.001), whereas no significant change was found in high-density lipoprotein cholesterol. No side effects were observed during the treatment period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>This study shows for the first time that anti-TNF-\u03b1 therapy for JIA is associated not only with a beneficial effect on clinical disease activity and inflammatory indexes, but also with improved lipid profile and oxidative stress. These findings suggest that TNF-\u03b1 blockers might reduce atherosclerotic risk in children with JIA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.121281","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T00:59:34Z","timestamp":1364864374000},"page":"943-948","source":"Crossref","is-referenced-by-count":24,"title":["Etanercept Improves Lipid Profile and Oxidative Stress Measures in Patients with Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"40","author":[{"given":"Sara","family":"De Sanctis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Loredana","family":"Marcovecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Del Torto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Mohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Chiarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2013,4,1]]},"reference":[{"key":"2018112909313803000_40.6.943.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370408"},{"key":"2018112909313803000_40.6.943.2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"2018112909313803000_40.6.943.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.11.007"},{"key":"2018112909313803000_40.6.943.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-008-0059-2"},{"key":"2018112909313803000_40.6.943.5","doi-asserted-by":"publisher","DOI":"10.2174\/138161211798764807"},{"key":"2018112909313803000_40.6.943.6","first-page":"U2125","article-title":"Atherogenic lipid profiles in rheumatoid arthritis","volume":"119","author":"White","year":"2006","journal-title":"NZ Med J"},{"key":"2018112909313803000_40.6.943.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135871"},{"key":"2018112909313803000_40.6.943.8","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2010.3365"},{"key":"2018112909313803000_40.6.943.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.24492"},{"key":"2018112909313803000_40.6.943.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.03.035"},{"key":"2018112909313803000_40.6.943.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.03.004"},{"key":"2018112909313803000_40.6.943.12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2174\/138161212799504795","article-title":"Rheumatoid arthritis: Cardiovascular manifestations, pathogenesis, and therapy","volume":"18","author":"Mellana","year":"2012","journal-title":"Curr Pharm Des"},{"key":"2018112909313803000_40.6.943.13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099844.31524.05"},{"key":"2018112909313803000_40.6.943.14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000037521.71373.44"},{"key":"2018112909313803000_40.6.943.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei033"},{"key":"2018112909313803000_40.6.943.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.601641"},{"key":"2018112909313803000_40.6.943.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0702-2"},{"key":"2018112909313803000_40.6.943.18","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.060708"},{"key":"2018112909313803000_40.6.943.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201148"},{"key":"2018112909313803000_40.6.943.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.24469"},{"key":"2018112909313803000_40.6.943.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0496-3"},{"key":"2018112909313803000_40.6.943.22","doi-asserted-by":"publisher","DOI":"10.1007\/BF03344156"},{"key":"2018112909313803000_40.6.943.23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.2.S2.555"},{"key":"2018112909313803000_40.6.943.24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.6.1175"},{"key":"2018112909313803000_40.6.943.25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0220"},{"key":"2018112909313803000_40.6.943.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.104"},{"key":"2018112909313803000_40.6.943.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904130"},{"key":"2018112909313803000_40.6.943.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.06.014"},{"key":"2018112909313803000_40.6.943.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"2018112909313803000_40.6.943.30","doi-asserted-by":"publisher","DOI":"10.1038\/nature00804"},{"key":"2018112909313803000_40.6.943.31","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R300019-JLR200"},{"key":"2018112909313803000_40.6.943.32","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0245"},{"key":"2018112909313803000_40.6.943.33","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)80113-4"},{"key":"2018112909313803000_40.6.943.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.06.001"},{"key":"2018112909313803000_40.6.943.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem089"},{"key":"2018112909313803000_40.6.943.36","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909313803000_40.6.943.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.22809"},{"key":"2018112909313803000_40.6.943.38","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0178"},{"key":"2018112909313803000_40.6.943.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04645.x"},{"key":"2018112909313803000_40.6.943.40","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.219"},{"key":"2018112909313803000_40.6.943.41","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1351.039"},{"key":"2018112909313803000_40.6.943.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.05.012"},{"key":"2018112909313803000_40.6.943.43","doi-asserted-by":"publisher","DOI":"10.1080\/13547500500215084"},{"key":"2018112909313803000_40.6.943.44","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800091-JLR200"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.121281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:25:51Z","timestamp":1543515951000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.121281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,1]]},"published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.3899\/jrheum.121281"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.121281","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,1]]}}}